Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with ...
Protein kinase inhibitors represent a major advance in cancer treatment due to their ability to target the specific kinases involved in tumor growth and survival. More than 80 small-molecule protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results